Novartis

Article

November 28, 2021

Novartis International AG is an international pharmaceutical and biotechnology company based in Basel, Switzerland. SIX Swiss Exchange, New York Stock Exchange listed companies (SIX: NOVN, NYSE: NVS). It was founded in 1996 by the merger of two Swiss-based pharmaceutical companies, Ciba Geigy and Sandoz. The company name Novartis is a coined word that combines "new" ("Nova") and "arts, technology" ("Artis"). Fortune Magazine's "World's Most Admired Companies 2013" has been named No. 1 Pharmaceutical Company for the third consecutive year. The following also describes Novartis Pharma K.K., a Japanese subsidiary of Novartis' pharmaceutical business.

Business

Novartis consists of three main divisions: research, medical product development, manufacturing and marketing. In addition to medical drugs and devices, over-the-counter drugs, health foods and contact lenses sold at drug stores. Etc. are also handled. In the past, it also handled veterinary drugs, but due to the separation of management, some products were handed over to Elanco, and the handling was terminated. Owns the following blockbuster products. Imatinib (anticancer drug) Diovan (Valsartan, hypertension) Ranibizumab (age-related macular degeneration) Octreotide (acromegaly) Amlodipine (hypertension) Zoledronic acid (osteoporosis) Fingolimod (multiple sclerosis) Rivastigmine (Alzheimer's disease)

History

1758: Founded in Basel by Geigy as a chemical and pharmaceutical wholesaler. 1864: Alexander Clavelle begins operations of a dye factory for silk fabrics in Basel. Then, in 1884, it became Basellschaft für Chemische Industrie Basel (CIBA). 1886: Alfred Khan and Eduardo Sand jointly start operation of a dye factory. Incorporated as Sandoz in 1895 after Khan's death. 1938: Sandoz succeeds in synthesizing LSD. 1939: Geigy scientist Paul Hermann Müller successfully creates DDT. 1971: Ciba and Geigy merge to become Ciba Geigy. December 1996: Ciba Geigy and Sandoz merge to become Novartis. At this time, the chemicals division such as dyes of Ciba Kaigy was separated as Ciba Specialty Chemicals. September 1997: Concluded a license agreement with Yoshitomi Pharmaceutical (currently Mitsubishi Tanabe Pharma) for the immunosuppressive agent under development. 1998: Signed a manufacturing and sales agreement on biotechnology with the University of California, Berkeley. 2000: Agricultural department and AstraZeneca's agricultural department merged to establish Syngenta. August 2000: Established Novartis Kao as a joint venture between Novartis Consumer Health and Kao. March 2002: Novartis Kao is dissolved due to unachieved achievements. June 2005: Acquired generic drug company Hexal (Germany) and merged with Novartis' generic business Sandoz. 2006: Acquired and merged with Chiron, a biopharmacy company in California, USA. August 2010: Acquired Archon, a major eye care company (Arcon became independent of Novartis in 2019).

Novartis Pharma

The Japanese subsidiary of Novartis is developing as follows, centered on the holding company Novartis Holding Japan Co., Ltd.

INSERT INTO `wiki_article`(`id`, `article_id`, `title`, `article`, `img_url`) VALUES ('NULL()','ノバルティス','Novartis','','https://upload.wikimedia.org/wikipedia/commons/2/24/Industria_Novartis.jpg')